Targeting treatment for ADAM30 in pathological cells
US12006550B2 · kind B2 · utility
0Cited by
26References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 12, 2021 |
| Grant date | Jun 11, 2024 |
| Priority date | — |
| Expiry date | Aug 12, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Described herein are methods and systems using ADAM30 as a biomarker to help early diagnosis of congenital malformed vasculatures in children and which can also serve as a companion diagnostic biomarker for malformed vasculatures, as well as a subpopulation of cancer cells, wherein blockage of activity of ADAM30 by a neutralized antibody or inhibitor can be used as a treatment strategy for those ADAM30-positive vascular endothelial cells and cancer cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.